Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Cytomx Therapeutics Inc patents


Recent patent applications related to Cytomx Therapeutics Inc. Cytomx Therapeutics Inc is listed as an Agent/Assignee. Note: Cytomx Therapeutics Inc may have other listings under different names/spellings. We're not affiliated with Cytomx Therapeutics Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Cytomx Therapeutics Inc-related inventors


Antibodies specific for urokinase-type plasminogen activator and methods of use thereof

The present disclosure relates to antibodies specific for urokinase-type plasminogen activator (upa). According to certain embodiments, the anti-upa antibody specifically binds to the active form of upa. ... Cytomx Therapeutics Inc

Antibodies that bind activatable antibodies and methods of use thereof

The invention relates generally to antibodies and antigen-binding fragments thereof that bind activatable antibodies and/or conjugated activatable antibodies and methods of making and using these antibodies that bind activatable antibodies and/or conjugated activatable antibodies.. . ... Cytomx Therapeutics Inc

Proproteins and methods of use thereof

The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. ... Cytomx Therapeutics Inc

Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof

The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (upa), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.. . ... Cytomx Therapeutics Inc

Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

The invention relates generally to activatable antibodies that include a masking moiety (mm), a cleavable moiety (cm), and an antibody (ab) that specifically binds to epidermal growth factor receptor (egfr), and to methods of making and using these anti-egfr activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.. . ... Cytomx Therapeutics Inc

Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

The invention relates generally to variant activatable antibodies that include a masking moiety (mm), a cleavable moiety (cm), and an antibody (ab) that specifically binds to epidermal growth factor receptor (egfr), and to methods of making and using these variant anti-egfr activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.. . ... Cytomx Therapeutics Inc

Modified antibody compositions, methods of making and using thereof

The present disclosure provides modified antibodies which contain an antibody or antibody fragment (ab) modified with a masking moiety (mm). Such modified antibodies can be further coupled to a cleavable moiety (cm), resulting in activatable antibodies (aas), wherein the cm is capable of being cleaved, reduced, photolysed, or otherwise modified. ... Cytomx Therapeutics Inc

Compositions and methods for conjugating activatable antibodies

The invention relates generally to compositions and methods for conjugating antibodies and activatable antibodies, and methods of partially reducing antibodies and/or activatable antibodies prior to conjugation, e.g., thiol-based conjugation, with an agent, e.g., a therapeutic and/or diagnostic agent.. . ... Cytomx Therapeutics Inc

Anti-pd1 antibodies, activatable anti-pd1 antibodies, and methods of use thereof

The invention relates generally to antibodies that specifically bind programmed cell death protein 1 (pd-1), activatable antibodies that specifically bind to pd-1 and methods of making and using these anti-pd-1 antibodies and anti-pd-1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.. . ... Cytomx Therapeutics Inc

Activatable antibodies that bind interleukin-6 receptor and methods of use thereof

The invention relates generally to activatable antibodies that include a masking moiety (mm), a cleavable moiety (cm), and an antibody (ab) that specifically binds to interleukin-6 receptor (il-6r), and to methods of making and using these anti-il-6r activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.. . ... Cytomx Therapeutics Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Cytomx Therapeutics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cytomx Therapeutics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###